Evaxion Biotech A/S Q2 2024 Earnings Report $3.09 -0.27 (-8.04%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Evaxion Biotech A/S EPS ResultsActual EPS-$0.60Consensus EPS $0.10Beat/MissMissed by -$0.70One Year Ago EPS-$10.50Evaxion Biotech A/S Revenue ResultsActual Revenue$0.15 millionExpected Revenue$0.10 millionBeat/MissBeat by +$50.00 thousandYoY Revenue GrowthN/AEvaxion Biotech A/S Announcement DetailsQuarterQ2 2024Date8/14/2024TimeBefore Market OpensConference Call ResourcesConference Call TranscriptEVAX Earnings History Evaxion Biotech A/S Earnings HeadlinesResearch Analysts Issue Forecasts for EVAX FY2024 EarningsJanuary 18 at 1:14 AM | americanbankingnews.comEvaxion Biotech stock hits 52-week low at $3.06 amid sharp declineJanuary 17 at 4:51 PM | msn.comKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. January 20, 2025 | Porter & Company (Ad)Evaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01January 16, 2025 | finanznachrichten.deEvaxion Biotech completes dosing in phase 2 trial with EVX-01January 16, 2025 | markets.businessinsider.comEvaxion concludes subject dosing in Phase II trial of melanoma vaccineJanuary 16, 2025 | finance.yahoo.comSee More Evaxion Biotech A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evaxion Biotech A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evaxion Biotech A/S and other key companies, straight to your email. Email Address About Evaxion Biotech A/SEvaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.View Evaxion Biotech A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
